Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 120
Filter
Add more filters

Publication year range
1.
J Pharm Pharm Sci ; 26: 11263, 2023.
Article in English | MEDLINE | ID: mdl-37122387

ABSTRACT

Purpose: An intraocular hemorrhage is an adverse event that can lead to visual acuity impairment. Antithrombotic therapy with antiplatelet agents and anticoagulants may increase intraocular hemorrhage. However, since their frequency is low, studies on the risk of intraocular hemorrhage with these drugs, especially under combination therapy, are limited. This study aimed to investigate the occurrence of intraocular hemorrhages under monotherapy and combination therapy with antiplatelets and anticoagulants by analyzing a large pharmacovigilance database. Methods: Intraocular hemorrhage signals with oral antiplatelets and anticoagulants were evaluated by calculating reporting odds ratios and information components using the Japan Adverse Drug Reactions Report database from April 2004 to March 2022. In addition, differences in signals between younger and elderly patients, affecting factors, and time-to-onset from initial antiplatelet and anticoagulant treatments were analyzed. Results: Aspirin, clopidogrel, warfarin, apixaban, and rivaroxaban, but not ticagrelor, ticlopidine, prasugrel, dabigatran, and edoxaban showed intraocular hemorrhage signals under monotherapy. In combination therapy, dual therapy (aspirin + P2Y12 inhibitors, warfarin, direct oral anticoagulants, and P2Y12 inhibitors + warfarin) and triple therapy (aspirin + P2Y12 inhibitors + warfarin) resulted in intraocular hemorrhage signals. Intraocular hemorrhage signals were observed in younger patients receiving monotherapy with aspirin and in elderly patients receiving monotherapy and combination therapy with warfarin. Affecting factors were diabetes mellitus in patients with prasugrel, use of medications for intravitreal injections, and posterior sub-Tenon injections with some antiplatelets and anticoagulants. The median period of intraocular hemorrhage occurrence after starting monotherapy with aspirin, clopidogrel, warfarin, or rivaroxaban was within 90 days. Conclusion: In addition to monotherapy with several antiplatelets and anticoagulants, combination therapy using aspirin, P2Y12 inhibitors, and warfarin has the potential risk of intraocular hemorrhage. Particular attention should be paid to the occurrence of intraocular hemorrhages in younger patients taking aspirin, in elderly patients taking warfarin, and within the first 90 days of antiplatelet and anticoagulant use.


Subject(s)
Anticoagulants , Eye , Hemorrhage , Aged , Humans , Anticoagulants/adverse effects , Aspirin/adverse effects , Clopidogrel/adverse effects , Drug Therapy, Combination , Hemorrhage/chemically induced , Platelet Aggregation Inhibitors/adverse effects , Prasugrel Hydrochloride/adverse effects , Rivaroxaban/adverse effects , Warfarin/therapeutic use , Japan , Adverse Drug Reaction Reporting Systems , Eye/pathology
2.
Mol Vis ; 26: 641-651, 2020.
Article in English | MEDLINE | ID: mdl-33088168

ABSTRACT

Purpose: Tofacitinib is a pan-Janus kinase (JAK) inhibitor that suppresses cytokine signaling and in turn, the cells that participate in inflammatory immunopathogenic processes. We examined the capacity of tofacitinib to inhibit the induction of experimental autoimmune uveitis (EAU) and related immune responses. Methods: EAU was induced in B10.A mice with immunization with bovine interphotoreceptor retinoid-binding protein (IRBP), emulsified in complete Freund's adjuvant (CFA), and a simultaneous injection of pertussis toxin. Tofacitinib, 25 mg/kg, was administered daily, and the vehicle was used for control. EAU development was assessed by histological analysis of the mouse eyes, and related immune responses were assessed by (i) the levels of interferon (IFN)-γ and interleukin (IL)-17, secreted by spleen cells cultured with IRBP; (ii) flow cytometric analysis of intracellular expression by spleen, or eye-infiltrating CD4 or CD8 cells of IFN-γ, IL-17, and their transcription factors, T-bet and RORγt. In addition, the inflammation-related cell markers CD44 and CD62L and Ki67, a proliferation marker, were tested. The proportions of T-regulatory cells expressing FoxP3 were determined by flow cytometric intracellular staining, while levels of antibody to IRBP were measured with enzyme-linked immunosorbent assay (ELISA). Results: Treatment with tofacitinib significantly suppressed the development of EAU and reduced the levels of secreted IFN-γ, but not of IL-17. Further, treatment with tofacitinib reduced in the spleen and eye-infiltrating cells the intracellular expression of IFN-γ and its transcription factor T-bet. In contrast, treatment with tofacitinib had essentially no effect on the intracellular expression of IL-17 and its transcription factor, RORγt. The selective effect of tofacitinib treatment was particularly evident in the CD8 population. Treatment with tofacitinib also increased the population of CD44, but reduced the populations of cells producing CD62L and Ki67. Treatment with tofacitinib had no effect on the proportion of FoxP3 producing regulatory cells and on the antibody production to IRBP. Conclusions: Treatment with tofacitinib inhibited the development of EAU, reduced the production of IFN-γ, but had essentially no effect on the production of IL-17.


Subject(s)
Eye/metabolism , Piperidines/pharmacology , Pyrimidines/pharmacology , Th1 Cells/drug effects , Th17 Cells/drug effects , Uveitis/drug therapy , Uveitis/immunology , Animals , CD4 Antigens/blood , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD8 Antigens/blood , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Eye/drug effects , Eye/pathology , Eye Proteins/pharmacology , Forkhead Transcription Factors/blood , Hyaluronan Receptors/blood , Immunosuppression Therapy , Interferon-gamma/blood , Interleukin-17/blood , Ki-67 Antigen/blood , L-Selectin/blood , Mice , Piperidines/administration & dosage , Pyrimidines/administration & dosage , Retinol-Binding Proteins/pharmacology , Th1 Cells/immunology , Th17 Cells/immunology
3.
J Vis Exp ; (161)2020 07 24.
Article in English | MEDLINE | ID: mdl-32773758

ABSTRACT

Spectral-domain optical coherence tomography (SD-OCT) is useful for visualizing retinal and ocular structures in vivo. In research, SD-OCT is a valuable tool to evaluate and characterize changes in a variety of retinal and ocular disease and injury models. In light induced retinal degeneration models, SD-OCT can be used to track thinning of the photoreceptor layer over time. In glaucoma models, SD-OCT can be used to monitor decreased retinal nerve fiber layer and total retinal thickness and to observe optic nerve cupping after inducing ocular hypertension. In diabetic rodents, SD-OCT has helped researchers observe decreased total retinal thickness as well as decreased thickness of specific retinal layers, particularly the retinal nerve fiber layer with disease progression. In mouse models of myopia, SD-OCT can be used to evaluate axial parameters, such as axial length changes. Advantages of SD-OCT include in vivo imaging of ocular structures, the ability to quantitatively track changes in ocular dimensions over time, and its rapid scanning speed and high resolution. Here, we detail the methods of SD-OCT and show examples of its use in our laboratory in models of retinal degeneration, glaucoma, diabetic retinopathy, and myopia. Methods include anesthesia, SD-OCT imaging, and processing of the images for thickness measurements.


Subject(s)
Eye Diseases/diagnostic imaging , Eye/diagnostic imaging , Eye/pathology , Tomography, Optical Coherence , Animals , Axial Length, Eye , Disease Models, Animal , Female , Image Processing, Computer-Assisted , Male , Mice, Inbred BALB C , Myopia/diagnostic imaging , Myopia/pathology , Photoreceptor Cells, Vertebrate/pathology , Rats , Retina/diagnostic imaging , Retina/pathology
4.
Int J Biol Macromol ; 162: 1699-1710, 2020 Nov 01.
Article in English | MEDLINE | ID: mdl-32777429

ABSTRACT

Improved ocular delivery of a poorly soluble anti-glaucoma drug, acetazolamide (ACZ), in a stable nanosuspension (NS) was the main target of the study. The anionic polypeptide, poly-γ-glutamic acid (PG) and the glycosaminoglycan, hyaluronic acid, were used to stabilize ACZ-NS prepared using the antisolvent precipitation (AS-PT) coupled with sonication technique. To endue in site biocompatibility with high tolerability, soya lecithin (SL) phospholipid has been also combined with polyvinyl alcohol (PVA). NS with uniform PS in the range 100-300 nm, high ζ > ±20 mV, and enhanced saturation solubility were produced. Targeting solvent removal with control on future particle growth, post-production processing of NS was done using spray drying. The carriers' composition and amount relative to ACZ-NS were optimized to allow for the production of a redispersible dry crystalline powder. Particles crystallinity was confirmed using X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) in liquid and spray dried NS. The modified Draize test proved the safety and tolerability following application to rabbit eyes accompanying an efficient ocular hypotensive activity using a steroid glaucoma model.


Subject(s)
Acetazolamide , Biocompatible Materials/therapeutic use , Drug Carriers/therapeutic use , Eye/drug effects , Glaucoma/drug therapy , Nanoparticles/therapeutic use , Acetazolamide/administration & dosage , Acetazolamide/pharmacokinetics , Animals , Biological Availability , Eye/pathology , Glycosaminoglycans/chemistry , Lecithins/chemistry , Peptides/chemistry , Polyvinyl Alcohol/chemistry , Rabbits , Glycine max/chemistry
5.
Arch Biochem Biophys ; 688: 108403, 2020 07 30.
Article in English | MEDLINE | ID: mdl-32418893

ABSTRACT

Myopia is a main cause of preventable or treatable visual impairment, it has become a major public health issue due to its increasingly high prevalence worldwide. Currently, it is confirmed that the development of myopia is associated with the disorders of accommodation. As a dominant factor for accommodation, ciliary muscle contraction/relaxation can regulate the physiological state of the lens and play a crucial role in the development of myopia. To investigate the relationship between myopia and ciliary muscle, the guinea pigs were randomly divided into a normal control (NC) group and a negative lens-induced myopia (LIM) group, and the animals in each group were further randomly assigned into 2-week (n = 18) and 4-week (n = 21) subgroups in accordance with the duration of myopic induction of 2 and 4 weeks, respectively. In the present study, right eyes of the animals in LIM group were covered with -6.0 D lenses to induce myopia. Next, we performed the haematoxylin and eosin (H&E) staining to observe the pathological change of ciliary muscle, determined the contents of adenosine triphosphate (ATP) and lactate acid (LA), and measured the Na+/K+-ATPase expression and activity in ciliary muscles in both NC and LIM groups. Moreover, we also analyzed the potassium ion (K+) flux in ciliary muscles from 4-week NC and LIM guinea pigs. As a result, we found that the arrangements of ciliary muscles in LIM guinea pigs were broken, dissolved or disorganized; the content of ATP decreased, whereas the content of LA increased in ciliary muscles from LIM guinea pigs. Monitoring of K+ flux in ciliary muscles from LIM guinea pigs demonstrated myopia-triggered K+ influx. Moreover, we also noted a decreased expression of Na+/K+-ATPase (Atp1a1) at both mRNA and protein levels and reduced activity in ciliary muscles from LIM guinea pigs. Overall, our results will facilitate the understanding of the mechanism associated with inhibitory Na+/K+-ATPase in lens-induced myopia and which consequently lead to the disorder of microenvironment within ciliary muscles from LIM guinea pigs, paving the way for a promising adjuvant approach in treating myopia in clinical practice.


Subject(s)
Eye/metabolism , Homeostasis/physiology , Muscle, Smooth/metabolism , Myopia/metabolism , Potassium/metabolism , Adenosine Triphosphate/metabolism , Animals , Eye/pathology , Guinea Pigs , Lactic Acid/metabolism , Male , Muscle, Smooth/pathology , Myopia/pathology , RNA, Messenger/metabolism , Sodium-Potassium-Exchanging ATPase/genetics , Sodium-Potassium-Exchanging ATPase/metabolism
6.
J Microbiol Immunol Infect ; 53(5): 766-777, 2020 Oct.
Article in English | MEDLINE | ID: mdl-30661953

ABSTRACT

PURPOSE: Postoperative endophthalmitis caused by nontuberculous mycobacterium is a rare but devastating complication after intraocular surgery. However, optimal treatment strategies remain undetermined in view of its rarity. METHODS: We investigated the cases of culture-proven postoperative Mycobacteroides abscessus subsp. abscessus endophthalmitis in southern Taiwan, focusing on clinical manifestations and microbiological study, and aimed to describe clinical staging and to propose a therapeutic modality for this disease. RESULTS: Twelve cases, including two published cases, were treated in two medical centers in southern Taiwan between Aug. 2011 and Dec. 2016, and all ever received cataract surgery at one clinic. Their disease courses could be categorized into four distinct stages, i.e., the initial, quiescent, recurrent, and end stage, and some cases experienced 1-4 cycles of quiescent-recurrent stages. Although all eyes ended up with phthisis or were eviscerated, the affected eyes receiving pars plana vitrectomy (PPV) tended to become quiescent and survived longer than those without PPV (adjusted hazard ratio: 13.9, p < 0.05). Eight isolates of eight patients were available for microbiological study. All isolates were susceptible to amikacin, and inducible clarithromycin resistance was observed in 100% of isolates. CONCLUSION: Despite the preservation of vision in postoperative M.abscessus endophthalmitis remained a challenge, a stage-based approach is proposed, which may facilitate decision-makings for the future study.


Subject(s)
Algorithms , Anti-Bacterial Agents/therapeutic use , Endophthalmitis/drug therapy , Mycobacterium abscessus/drug effects , Postoperative Complications/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Amikacin/therapeutic use , Clarithromycin/therapeutic use , Endophthalmitis/microbiology , Endophthalmitis/pathology , Eye/pathology , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium Infections, Nontuberculous/drug therapy , Nontuberculous Mycobacteria , Taiwan , Vitrectomy , Young Adult
7.
Biomed Res Int ; 2019: 8080564, 2019.
Article in English | MEDLINE | ID: mdl-31886253

ABSTRACT

PURPOSE: To determine the effects of selenium, melatonin, and selenium + melatonin administered for one month on anterior chamber (AC) malondialdehyde (MDA) and AC glutathione (GSH) levels in patients with ocular ischemic syndrome. MATERIALS AND METHODS: Thirty-five patients were included in the study. Study groups were formed as follows: (1) control group, (2) ischemia group, (3) selenium + ischemia group, (4) melatonin + ischemia group, and (5) selenium + melatonin + ischemia group. AC samples were obtained. MDA and GSH levels in AC samples were evaluated. RESULTS: MDA levels were significantly increased in ischemia groups. Selenium and melatonin supplementation resulted in reduction of MDA levels and significant increase in GSH values. DISCUSSION: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium and melatonin supplementation. This trial is registered with ClinicalTrials.gov NCT04005222.


Subject(s)
Eye/blood supply , Ischemia/drug therapy , Melatonin/therapeutic use , Selenium/therapeutic use , Aged , Aged, 80 and over , Eye/pathology , Female , Glutathione/metabolism , Humans , Male , Malondialdehyde , Melatonin/pharmacology , Middle Aged , Selenium/pharmacology , Syndrome
8.
Pharmacol Res Perspect ; 7(6): e00545, 2019 12.
Article in English | MEDLINE | ID: mdl-31763044

ABSTRACT

Age-related macular degeneration (AMD) is the leading cause of severe vision impairment in patients over the age of 60 years. Choroidal neovascularization (CNV) is the hallmark of neovascular AMD and vascular endothelial growth factor (VEGF) plays a causal role in the formation of CNV. Although regorafenib and pazopanib, small molecule VEGF receptor (VEGFR) inhibitors, were developed as eye-drops, their efficacies were insufficient in clinical. In this study, we evaluated ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib after ocular instillation in multiple animal species. In rats, both regorafenib and pazopanib showed high enough concentrations in the posterior eye tissues to inhibit VEGFR. In laser-induced rat CNV model, regorafenib showed clear reduction in CNV area. On the other hand, the concentrations of regorafenib and pazopanib in the posterior eye tissues were much lower after ocular instillation in rabbits and monkeys compared to those in rats. Pazopanib did not show any improvement in monkey model. Regorafenib was nano-crystalized to improve its drug delivery to the posterior eye tissues. The nano-crystalized formulation of regorafenib showed higher concentrations in the posterior segments in rabbits compared to its microcrystal suspension. From these studies, large interspecies differences were found in ocular delivery to the posterior segments after ocular instillation. Such large interspecies difference could be the reason for the insufficient efficacies of regorafenib and pazopanib in clinical studies. Nano-crystallization was suggested to be one of the effective ways to overcome this issue.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Choroidal Neovascularization/drug therapy , Macular Degeneration/drug therapy , Phenylurea Compounds/pharmacology , Pyridines/pharmacology , Pyrimidines/pharmacology , Sulfonamides/pharmacology , Angiogenesis Inhibitors/therapeutic use , Animals , Choroidal Neovascularization/etiology , Choroidal Neovascularization/pathology , Crystallization , Disease Models, Animal , Drug Evaluation, Preclinical , Eye/metabolism , Eye/pathology , Female , Humans , Indazoles , Macaca fascicularis , Macular Degeneration/etiology , Macular Degeneration/pathology , Male , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Ophthalmic Solutions/pharmacology , Ophthalmic Solutions/therapeutic use , Particle Size , Phenylurea Compounds/chemistry , Phenylurea Compounds/therapeutic use , Pyridines/chemistry , Pyridines/therapeutic use , Pyrimidines/chemistry , Pyrimidines/therapeutic use , Rabbits , Rats , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Species Specificity , Sulfonamides/chemistry , Sulfonamides/therapeutic use , Vascular Endothelial Growth Factor A/metabolism
9.
JCI Insight ; 3(19)2018 10 04.
Article in English | MEDLINE | ID: mdl-30282825

ABSTRACT

Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK+ cells expressing B220 or F4/80, resembling SYK+ cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.


Subject(s)
Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Indazoles/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Pyrazines/administration & dosage , Syk Kinase/antagonists & inhibitors , Administration, Oral , Animals , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Disease Models, Animal , Drug Evaluation, Preclinical , Eye/drug effects , Eye/immunology , Eye/pathology , Female , Graft vs Host Disease/immunology , Graft vs Host Disease/mortality , Humans , Mice , Skin/drug effects , Skin/immunology , Skin/pathology , Survival Analysis , Syk Kinase/immunology , Syk Kinase/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Treatment Outcome
10.
Toxicol Pathol ; 46(7): 799-820, 2018 10.
Article in English | MEDLINE | ID: mdl-30348063

ABSTRACT

Information on background changes in the ocular tissues of rabbits ( Oryctolagus cuniculus), a common species employed in ophthalmic toxicology studies, is sparse. This complicates interpretation of changes in light of small sample sizes on any single study. The purpose of this publication is to document the interstudy incidence of spontaneous or iatrogenic changes occurring in eyes of control rabbits. Photomicrographs of select lesions are provided. The data set was derived from a total of 54 studies conducted over an eleven-year period at Alcon Research Ltd., a Novartis Division, which featured topical ocular and contact lens routes of administration. It includes a total of 1,222 pigmented and albino New Zealand rabbits and a total of 2,084 eyes which were either untreated or treated with innocuous control articles. There were no noteworthy differences across routes of administration. Changes in anterior segment ocular and adnexal tissues were more common than in posterior segment ocular tissues. Overall, mononuclear cell infiltration was the most common finding. The retina was the posterior tissue most commonly observed with spontaneous changes, with folds and rosettes being the most common retinal finding. Retinal changes were more common in albino as compared to pigmented rabbits. Understanding the incidence and characteristics of spontaneous ocular lesions facilitates accurate and consistent diagnosis and data interpretation.


Subject(s)
Control Groups , Eye/pathology , Lenses, Intraocular/adverse effects , Administration, Ophthalmic , Animals , Cornea/drug effects , Cornea/pathology , Drug Evaluation, Preclinical , Eye/drug effects , Eyelids/drug effects , Eyelids/pathology , Female , Male , Pharmaceutical Preparations/administration & dosage , Rabbits , Retina/drug effects , Retina/pathology , Retrospective Studies
11.
Nutrients ; 10(9)2018 Sep 18.
Article in English | MEDLINE | ID: mdl-30231532

ABSTRACT

Lutein is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health. In particular, lutein is known to improve or even prevent age-related macular disease which is the leading cause of blindness and vision impairment. Furthermore, many studies have reported that lutein may also have positive effects in different clinical conditions, thus ameliorating cognitive function, decreasing the risk of cancer, and improving measures of cardiovascular health. At present, the available data have been obtained from both observational studies investigating lutein intake with food, and a few intervention trials assessing the efficacy of lutein supplementation. In general, sustained lutein consumption, either through diet or supplementation, may contribute to reducing the burden of several chronic diseases. However, there are also conflicting data concerning lutein efficacy in inducing favorable effects on human health and there are no univocal data concerning the most appropriate dosage for daily lutein supplementation. Therefore, based on the most recent findings, this review will focus on lutein properties, dietary sources, usual intake, efficacy in human health, and toxicity.


Subject(s)
Diet , Dietary Supplements , Eye Diseases/prevention & control , Eye , Lutein/administration & dosage , Animals , Eye/metabolism , Eye/pathology , Eye/physiopathology , Eye Diseases/metabolism , Eye Diseases/pathology , Eye Diseases/physiopathology , Humans , Nutritional Status , Nutritive Value , Prognosis , Protective Factors , Risk Factors
12.
Nutrients ; 10(6)2018 May 24.
Article in English | MEDLINE | ID: mdl-29795004

ABSTRACT

Polyunsaturated fatty acids (PUFA) are known to have numerous beneficial effects, owing to their anti-inflammatory and antioxidant properties. From a metabolic standpoint, the mitochondria play a fundamental role in cellular homeostasis, and oxidative stress can affect their functioning. Indeed, the mitochondria are the main source of ROS, and an imbalance between ROS and antioxidant defenses leads to oxidative stress. In addition, aging, the decline of cellular functions, and continual exposure to light underlie many diseases, particularly those of the eye. Long-term exposure to insults, such as UV light, visible light, ionizing radiation, chemotherapeutics, and environmental toxins, contribute to oxidative damage in ocular tissues and expose the aging eye to considerable risk of pathological consequences of oxidative stress. Ample antioxidant defenses responsible for scavenging free radicals are essential for redox homeostasis in the eye, indeed, eye tissues, starting from the tear film, which normally are exposed to high oxygen levels, have strong antioxidant defenses that are efficient for protecting against ROS-related injuries. On the contrary, instead, the trabecular meshwork is not directly exposed to light and its endothelial cells are poorly equipped with antioxidant defenses. All this makes the eye a target organ of oxidative damage. This review focuses on the role of the polyunsaturated fatty acids in the human eye, particularly in such pathologies as dry eye, glaucoma, and macular degeneration, in which dietary PUFA supplementation can be a valid therapeutic aid.


Subject(s)
Dietary Supplements , Eye Diseases/prevention & control , Eye/metabolism , Fatty Acids, Unsaturated/administration & dosage , Oxidative Stress , Animals , Antioxidants/metabolism , Eye/pathology , Eye Diseases/epidemiology , Eye Diseases/metabolism , Eye Diseases/pathology , Fatty Acids, Unsaturated/metabolism , Humans , Protective Factors , Reactive Oxygen Species/metabolism , Risk Factors
13.
Graefes Arch Clin Exp Ophthalmol ; 256(5): 879-884, 2018 May.
Article in English | MEDLINE | ID: mdl-29532171

ABSTRACT

AIM: The aim of this study is to determine whether there is any difference in the quality of life of patients with a blind eye with long-term silicone oil compared to without. METHOD: Patients with either long-term silicone oil in situ (N = 17), defined as a period greater than 6 months duration with no plan for future removal, or those with a phthisical, non oil-filled eye were identified (N = 13). Two validated questionnaires (NEI VFQ-25 and the FACE-Q) that cover indicators for visual function, pain and cosmesis were sent to all patients in the two cohorts. RESULTS: There was no significant difference found in quality of life outcomes between the two groups in terms of visual function, pain or cosmesis. CONCLUSION: The results of this study support a holistic approach to the consent process before vitreoretinal surgery. Patients that may need to undergo multiple vitreoretinal procedures, where the endstage result is a long-term silicone oil fill, should be informed that their functional outcome may be similar to having no surgical intervention.


Subject(s)
Blindness/psychology , Eye/pathology , Quality of Life/psychology , Retinal Detachment/psychology , Silicone Oils/administration & dosage , Adult , Aged , Aged, 80 and over , Atrophy/psychology , Endotamponade , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retinal Detachment/surgery , Sickness Impact Profile , Surveys and Questionnaires , Visual Acuity/physiology , Vitrectomy , Vitreoretinal Surgery
14.
Inflamm Res ; 67(2): 117-127, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29127443

ABSTRACT

INTRODUCTION: Graves' orbitopathy (GO) is an autoimmune inflammatory disorder affecting the orbit around the eye. Astragaloside IV (AS-VI) is the main active ingredient of the Chinese herbal medicine Huangqi (Radix Astragali Mongolici). AS-IV exhibits antioxidant and anti-inflammatory properties, and shows therapeutic potential in a number of ischemic and inflammatory diseases; however, its pharmaceutical activities in GO remain undefined. MATERIALS AND METHODS: In this study, we investigated the effects of AS-IV on interleukin (IL)-1ß-induced orbital fibroblast inflammation in vitro and GO orbital inflammation and ocular histopathological changes in vivo, as well as the underlying mechanisms responsible for these effects. RESULTS AND CONCLUSION: The results show that IL-1ß increased mRNA expression of the inflammatory cytokines IL-6, IL-8, TNF-α, and MCP-1 in cultured orbital fibroblasts. This IL-1ß-induced inflammation was accompanied by increased autophagic activity as reflected in increased Beclin-1 and Agt-5 expression, as well as LC3-I to LC3-II conversion. Pretreatment with the autophagy inhibitors 3-MA and bafilomycin A1, or silencing of autophagy-related proteins Beclin-1 and Atg-5, prevented IL-1ß-induced orbital fibroblast inflammation, while pretreatment with the autophagy activator rapamycin had the opposite effects. These data suggested that autophagy was involved in GO orbital inflammation. AS-IV treatment significantly decreased IL-1ß-induced inflammatory cytokine production in orbital fibroblasts in vitro and attenuated GO orbital inflammation, fat accumulation, collagen deposition, and macrophage infiltration in vivo. These in vitro and in vivo protective effects of AS-IV against GO were accompanied by decreased autophagic activities in orbital fibroblasts and GO orbital tissues, respectively. Collectively, our findings suggested that AS-IV protects against GO through suppression of autophagy. Thus, AS-IV may have preventive benefits for GO.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Autophagy/drug effects , Graves Disease/drug therapy , Graves Disease/pathology , Orbit/pathology , Saponins/therapeutic use , Triterpenes/therapeutic use , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cells, Cultured , Cytokines/biosynthesis , Eye/pathology , Female , Fibroblasts/drug effects , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/pharmacology , Mice , Mice, Inbred BALB C , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Saponins/pharmacology , Triterpenes/pharmacology
15.
Biomed Res Int ; 2017: 7190987, 2017.
Article in English | MEDLINE | ID: mdl-28904968

ABSTRACT

OBJECTIVE: To investigate the prevalence and features of ocular allergy (OA) and comorbidities among school children in Shanghai, China. METHODS: This was a population-based cross-sectional study. Each participant completed an ISAAC-based questionnaire. The prevalence of OA symptoms, allergic rhinitis (AR) asthma, atopic dermatitis (AD), and sensitization to mites, pollen, and food was analyzed. RESULTS: A total of 724 and 942 completed questionnaires from the 7-9-year-old (young group) and the 12-14-year-old (teen group) groups were analyzed, respectively. The overall prevalence of OA symptoms was 28%. However, more young students (10.6%) reported mild to severe daily life interference caused by OA than the teens (5.7%). The young group had higher prevalence of diagnosed allergic conjunctivitis (10.2%). The overall prevalence of AR symptom, diagnosed asthma, and diagnosed AD was 40.4%, 11.6%, and 16.7%, respectively. Young children had higher prevalence of diagnosed AR and AD than the teens. There were gender associated differences in the prevalence of AR and asthma among young children, but not among the teens. The comorbidities associated with OA was also analyzed. Sensitization to mites, food, and pollen was associated with higher prevalence of allergic conditions. CONCLUSIONS: OA together with other allergic conditions affected a significant number of children in Shanghai.


Subject(s)
Asthma/epidemiology , Conjunctivitis, Allergic/epidemiology , Dermatitis, Atopic/epidemiology , Rhinitis, Allergic/epidemiology , Adolescent , Allergens/adverse effects , Animals , Child , China/epidemiology , Conjunctivitis, Allergic/pathology , Dermatitis, Atopic/pathology , Eye/pathology , Female , Food Hypersensitivity , Humans , Male , Mites , Pollen/adverse effects , Rhinitis, Allergic/pathology , Surveys and Questionnaires
16.
Sci Rep ; 7(1): 8238, 2017 08 15.
Article in English | MEDLINE | ID: mdl-28811672

ABSTRACT

Nonporous silica nanoparticles (SiNPs) have potential as promising carriers for ophthalmic drugs. However, the in vivo safety of ocular topical SiNPs remains unclear. This study investigated the in vivo safety of oral and ocular topical applications of 100 nm-sized SiNPs in Sprague-Dawley rats. The rats were divided into the following four groups: low-dose oral administration (total 100 mg/kg of SiNPs mixed with food for one week), high-dose oral administration (total 1000 mg/kg of SiNPs mixed with food for one week), ocular topical administration (10 mg/ml concentration, one drop, applied to the right eyes four times a day for one month), or a negative control (no SiNP treatment). The rats were observed for 12 weeks to investigate any signs of general or ocular toxicity. During the observation period, no differences were observed in the body weights, food and water intakes, behaviors and abnormal symptoms of the four groups. No animal deaths occurred. After 12 weeks, hematologic, blood biochemical parameters and ophthalmic examinations revealed no abnormal findings in any of the animals. The lack of toxicity of the SiNPs was further verified in autopsy findings of brain, liver, lung, spleen, heart, kidneys, intestine, eyeballs, and ovaries or testes.


Subject(s)
Nanoparticles , Silicon Dioxide , Administration, Oral , Administration, Topical , Animals , Biomarkers , Diagnostic Techniques, Ophthalmological , Drug Carriers/chemistry , Drug Delivery Systems , Eye/drug effects , Eye/pathology , Female , Immunohistochemistry , Male , Nanoparticles/administration & dosage , Nanoparticles/adverse effects , Nanoparticles/chemistry , Organ Size , Rats , Silicon Dioxide/chemistry
17.
Environ Toxicol Pharmacol ; 50: 83-90, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28135653

ABSTRACT

The eye is a sensitive organ with complex optical system involves in the perception of light. Although it has several protective mechanisms by itself, various physiological and metabolic disorders are detrimental to the proper functioning of the visual system. Grape juice has long been used worldwide for its potent medicinal values including ocular promotion. Bioactivities of grape products are highly attributed to the presence of health promoting phytochemicals in them. Some phytochemicals present in the grape juice have been involved in the maintenance of intra-ocular pressure, regulation of glucose metabolisms and suppression of pro-inflammatory cytokines in the system. Particularly, the grape derived phytochemicals involve in minimizing various eye defects such as macular degradation, uvea, cataract formation, red eye, diabetic retinopathy and so on. However, only limited number of studies has been conducted so far focusing the ocular promoting activity of grape polyphenols. In this review, we discuss the role of grape polyphenols in ocular promotion relating their anti-oxidant, anti-microbial, anti-aging, anti-hypertensive and anti-inflammatory properties.


Subject(s)
Eye/drug effects , Polyphenols/pharmacology , Vitis/chemistry , Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Antihypertensive Agents/pharmacology , Antioxidants/pharmacology , Eye/microbiology , Eye/pathology , Humans , Plant Extracts/chemistry , Plant Extracts/pharmacology
18.
J Hazard Mater ; 321: 690-702, 2017 Jan 05.
Article in English | MEDLINE | ID: mdl-27701059

ABSTRACT

This study reveals protective role of l-ascorbic acid (25, 50 and 100µg/mL) against toxic impacts of acute sub-lethal exposure of Acephate (5µg/mL) in a non-target organism Drosophila melanogaster. Organismal effect was evident from increased impairment in climbing activities (9 folds) of treated individuals who also manifested altered ocular architecture. These anomalies were reduced with l-ascorbic acid (l-AA) supplementation. Acephate induced apoptotic lesions in eye imaginal discs and gut confirmed tissue damage that also reduced with l-AA co-treatment. Reduction in viability of fat body cells (∼41%), neural cells (∼42%) and hemocytes (3 folds) indicates cytotoxic and immunotoxic potential of Acephate, which were significantly mitigated with l-AA co-administration. The sub-cellular toxic impacts of Acephate treatment became obvious from enhancement in activities of antioxidant enzymes (CAT by ∼1.63 folds, SOD by ∼1.32 folds), detoxifying enzymes (Cyp450 by ∼1.99 folds and GST by ∼1.34 folds), 2.1 times boost in HSP 70 expression, and inhibition of cholinesterase activity (by ∼0.66 folds). DNA breaks evident through comet assay confirmed Acephate triggered genotoxicity which could also be prevented through co-administration of. L-AA Furthermore, the study proposes the use of Drosophila as a model to screen chemicals for their protective potential against pesticide toxicity.


Subject(s)
Antioxidants/pharmacology , Ascorbic Acid/pharmacology , Insecticides/toxicity , Organothiophosphorus Compounds/antagonists & inhibitors , Organothiophosphorus Compounds/toxicity , Phosphoramides/antagonists & inhibitors , Phosphoramides/toxicity , Protective Agents/pharmacology , Animals , Antioxidants/metabolism , Apoptosis/drug effects , Behavior, Animal/drug effects , Cell Survival/drug effects , DNA Damage , Drosophila melanogaster , Eye/drug effects , Eye/pathology , Fat Body/drug effects , Gene Expression Regulation/drug effects , Hepatocytes/drug effects , Larva , Motor Activity/drug effects , Neurons/drug effects , Protein Synthesis Inhibitors/toxicity
19.
Cutan Ocul Toxicol ; 36(1): 52-59, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27160797

ABSTRACT

CONTEXT: The study was carried out to evaluate the effect of the aqueous fruit pericarp extract of Litchi chinensis (APLC) on parameters which leads to diabetic cataractogenesis and retinopathy in the streptozotocin-induced diabetic rats. OBJECTIVE: The objective of the study is to evaluate the APLC for in vivo antioxidant activity and its role in inhibiting the polyol pathway and formation of advanced glycation end products (AGEs). MATERIALS AND METHODS: The diabetic animals were treated with L. chinensis for a period of 12 weeks. At the end of 12 weeks, the animals were killed and the biochemical pathways involved in the pathogenesis of cataract such as oxidative stress by protein content, superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and polyolpathway by aldose reductase (AR) in lens homogenates, alterations in protein carbonyl content (PCO) and AGEs in both serum and lens the APLC-treated diabetic rats were compared against diabetic control rats. Cataract progression due to hyperglycemia was monitored by slit lamp bio microscope and classified into four stages. Fundoscope test and retinal histopathology were done for assessing retinopathy. RESULTS: Statistically significant reduction in glucose, and elevation of protein content, SOD, CAT, and GSH levels and decreased levels of AR and PCO in lens homogenate and significant reduction in AGEs serum and lens homogenate were observed. Slit lamp examination, fundoscope, and histopathology showed improvement in retinal changes in APLC-treated rats compared to diabetic control animals. CONCLUSION: The treatment with APLC found to delay the progression of diabetic cataractogenesis and retinopathy, which might be due to its antioxidant activity, because of the presence of active phytochemicals in APLC.


Subject(s)
Antioxidants/therapeutic use , Cataract/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Litchi , Plant Extracts/therapeutic use , Retinal Diseases/drug therapy , Animals , Antioxidants/pharmacology , Blood Glucose/analysis , Catalase/metabolism , Cataract/blood , Cataract/metabolism , Cataract/pathology , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Eye/drug effects , Eye/metabolism , Eye/pathology , Fruit , Glutathione/metabolism , Glycation End Products, Advanced/blood , Glycation End Products, Advanced/metabolism , Hyperglycemia/blood , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Hyperglycemia/pathology , Male , Phytotherapy , Plant Extracts/pharmacology , Protein Carbonylation/drug effects , Rats, Wistar , Retinal Diseases/blood , Retinal Diseases/metabolism , Retinal Diseases/pathology , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL